Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pharmacist Average Monthly Salary Down 9,636 Yen: Survey
August 19, 2019
- Osaka Univ. Spinout StemRIM Makes Tepid TSE Debut
August 16, 2019
- Towa Starts Joint Research with National CV Center on Disease Prevention, Healthy Life Expectancy Extension
August 16, 2019
- AstraZeneca Japan Adjusts Company Rules for Same-Sex, Common-Law Couples
August 16, 2019
- Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
August 9, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Ono Seeks Label Expansion for Onoact Sepsis-Associated Tachyarrhythmia
August 9, 2019
- Mitsubishi Tanabe’s Schizophrenia Drug Cariprazine Approved in 2 Asian Nations
August 9, 2019
- Mitsubishi Tanabe Submits PI Study Protocol for Spinal Cord Injury Treatment MT-3921 in US
August 9, 2019
- Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
- Mitsubishi Tanabe’s ALS Drug Gains Chinese Approval
August 8, 2019
- Meiji Launches 2 Santen Eye Drugs in Indonesia
August 8, 2019
- Life Science Institute’s Muse Cell Product Processing Facility Bags Manufacturing License
August 8, 2019
- Japan Ethical Drug Sales Up 0.2% in June: Crecon
August 8, 2019
- Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
- Keytruda Top-Selling Drug in Japan in April-June: IQVIA
August 7, 2019
- PIII Gets Underway for Astellas’ Hot Flash Drug Fezolinetant
August 7, 2019
- Mitsubishi Tanabe, Jichi Medical Univ. to Commence AMED-Funded Hemophilia Gene Therapy Research
August 7, 2019
- Rohto President “Frustrated” with Slow Pace of Rx-to-OTC Switches in Japan
August 7, 2019
- Suzuken, SanBio Join Forces for Commercial Distribution of Stem Cell Therapy
August 7, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…